PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has released its financial results for the third quarter of 2024, alongside updates on significant developments, particularly concerning its lead product candidate, INO-3107. This innovative solution is aimed at providing a non-surgical option for Recurrent Respiratory Papillomatosis (RRP) patients, a key focus for the company.
Recent data presented at major conferences demonstrated that INO-3107 can effectively induce antigen-specific cytotoxic T cell responses against HPV-6 and HPV-11. These responses are crucial as they recruit T cells into airway tissues and papillomas, potentially reducing the frequency of surgeries needed for RRP patients. Dr. Jacqueline Shea, INOVIO’s President and CEO, emphasized the company’s dedication to advancing INO-3107: “We continue to be focused on advancing INO-3107 and delivering a non-surgical option to RRP patients. Our development of INO-3107 is supported by a growing body of research that collectively points to INO-3107’s potential to be an important therapeutic option for all RRP patients regardless of the severity of their disease.”
INOVIO is on track to complete all non-device Biologics License Application (BLA) modules by the end of 2024, with the BLA submission targeted for mid-2025. The company expects to announce long-term clinical durability data by year’s end, underscoring INO-3107’s promise as a preferred choice for patients, healthcare providers, and payors.
Financially, INOVIO reported a net loss of $25.2 million for the third quarter of 2024, an improvement from the $33.9 million loss in the same period of 2023. Research and Development expenses rose to $18.7 million, reflecting increased drug manufacturing and device development costs. However, General and Administrative expenses decreased to $8.6 million, owing to reduced employee compensation and legal expenses.
INOVIO’s cash, cash equivalents, and short-term investments stood at $84.8 million as of September 30, 2024. The company estimates its cash resources will extend into the third quarter of 2025, excluding any additional capital-raising activities.
As part of its broader pipeline, INOVIO is also preparing for a Phase 3 trial of INO-3112 for HPV-related throat cancer and a Phase 2 trial of INO-4201 as a booster for the Ebola vaccine Ervebo®. Discussions for these trials are ongoing with regulators in North America and Europe.
Dr. Shea concluded, “We continue to believe INO-3107 has the potential to become the preferred choice for the broadest number of RRP patients, healthcare providers, and payors, if approved.”
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.